UK markets close in 45 minutes

IQVIA Holdings Inc. (IQV)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
230.86-0.63 (-0.27%)
As of 10:45AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close231.49
Open229.31
Bid231.03 x 900
Ask231.09 x 800
Day's range227.40 - 232.46
52-week range128.52 - 237.47
Volume301,491
Avg. volume941,796
Market cap44.247B
Beta (5Y monthly)1.46
PE ratio (TTM)109.93
EPS (TTM)2.10
Earnings date20 Jul 2021 - 26 Jul 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est256.32
  • Business Wire

    U.S. District Court Issues Favorable Decision for IQVIA Against Veeva

    IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the U.S. District Court of New Jersey issued a favorable decision in its litigation with Veeva Systems, Inc. (NYSE:VEEV). The Court ruled on IQVIA’s motion for sanctions, finding Veeva engaged in massive destruction of evidence, engaged in a cover-up of its wrong-doing, and repeatedly lied about its actions. The court sanctioned Veeva five separate times in the decision to punish Veeva for its violations of rules in the litigation, including multiple adverse jury instructions, limitations on the use of evidence at trial and an award of legal fees and costs. Specific language from the decision includes:

  • 3 Reasons Why Growth Investors Shouldn't Overlook IQVIA (IQV)
    Zacks

    3 Reasons Why Growth Investors Shouldn't Overlook IQVIA (IQV)

    IQVIA (IQV) could produce exceptional returns because of its solid growth attributes.

  • Business Wire

    IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug

    IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older.